
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a biopharmaceutical company with a promising drug in development for schizophrenia and Alzheimer's disease psychosis. Their focus on safety and efficacy, as well as the potential for success in other neuropsychiatric disorders, presents opportunities for growth. However, competition and pipeline risks should be considered. Ongoing clinical trials will be key in determining the success and market impact of their drug.
Bears say
MapLight Therapeutics is facing a challenging market with a highly competitive landscape and a long period of drug development before product commercialization. There is little financial data available for the company besides its impressive discovery platform and promising phase 2 trial results, making it difficult to accurately assess its financial standing and potential for success. Additionally, the success of ML-007C-MA relies heavily on the results of ongoing clinical trials and regulatory approval, which are subject to uncertainty and potential setbacks.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares